FeesSafety
Pluang+

GE Aerospace poised for 15% annual returns through 2030, driven by market dominance and strategic acquisitions.

Analyst Insights
14 Sep 2026
Seeking Alpha
View Source
Bullish
GE Aerospace poised for 15% annual returns through 2030, driven by market dominance and strategic acquisitions.

GE Aerospace holds a strong competitive position in the narrowbody engine market and benefits from growing end markets. The recent CPP acquisition is expected to help GE regain value from parts suppliers amid a tight market for high-performance castings. Earnings per share (EPS) growth is projected in the mid-teens, supported by the LEAP engine rollout, operating leverage, and shareholder-friendly capital allocation. Despite a high valuation, the stock is fairly priced with an estimated 15% annual total shareholder return potential through 2030, assuming no multiple expansion.

GE Aerospace is the subject of this report, with Pluang market data providing context as of Sep 15, 2026 03:21 WIB. For readers following the Industrials sector, 38 of 75 priced US stocks rose while 36 fell today. Notable movers include BIP at USD 35.65 down 3.34%, PWR at USD 628.91 down 3.33%, and LYFT at USD 15.83 up 3.33%.

More News

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
45 minutes ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
45 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
45 minutes ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
1 hour ago
Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App